AstraZeneca and Abbisko collaborate on NSCLC combination therapy trial

AstraZeneca has signed a strategic collaboration agreement with Abbisko Therapeutics to study the combined use of Tagrisso and lumipodlin in patients with NSCLC. Abbisko will lead the study, with both companies jointly sharing clinical trial responsibilities. AstraZeneca continues to explore Tagrisso in multiple indications for EGFR-mutant NSCLC. Credit: Innovative Creation/Shutterstock.com. AstraZeneca has signed a strategic collaboration agreement with Abbisko Therapeutics to study the combined use of Tagrisso (osimertinib) and lumipodlin (ABSK043) in patients with non-small cell lung cancer (NSCLC). The multicentre, open-label Phase I/II trial will assess the safety and efficacy of the combination in patients with epidermal growth factor…

Source: Clinical Trials Arena